DAFNA Capital Management LLC Increases Position in UroGen Pharma Ltd. (NASDAQ:URGN)

DAFNA Capital Management LLC boosted its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 7.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 492,515 shares of the company's stock after purchasing an additional 33,600 shares during the quarter. UroGen Pharma makes up 1.3% of DAFNA Capital Management LLC's holdings, making the stock its 19th largest position. DAFNA Capital Management LLC owned about 2.10% of UroGen Pharma worth $5,245,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Barclays PLC lifted its position in shares of UroGen Pharma by 409.3% during the 3rd quarter. Barclays PLC now owns 59,778 shares of the company's stock valued at $759,000 after buying an additional 48,040 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in UroGen Pharma by 263.1% during the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company's stock valued at $864,000 after purchasing an additional 49,318 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of UroGen Pharma in the fourth quarter valued at about $1,472,000. Bank of New York Mellon Corp increased its stake in shares of UroGen Pharma by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock worth $1,001,000 after purchasing an additional 6,430 shares in the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in UroGen Pharma in the 4th quarter valued at about $126,000. 91.29% of the stock is owned by institutional investors and hedge funds.

UroGen Pharma Price Performance

Shares of NASDAQ:URGN opened at $10.12 on Thursday. The company has a 50-day moving average price of $10.60 and a 200 day moving average price of $11.02. UroGen Pharma Ltd. has a 52 week low of $8.94 and a 52 week high of $20.70. The company has a market cap of $466.74 million, a P/E ratio of -3.21 and a beta of 0.66. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The firm had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. Research analysts predict that UroGen Pharma Ltd. will post -3.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

URGN has been the topic of a number of analyst reports. Scotiabank started coverage on UroGen Pharma in a research report on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 price objective on the stock. HC Wainwright restated a "buy" rating and issued a $55.00 price objective on shares of UroGen Pharma in a report on Monday, April 28th. The Goldman Sachs Group dropped their price objective on UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Guggenheim reissued a "buy" rating on shares of UroGen Pharma in a report on Tuesday, April 29th. Finally, D. Boral Capital reissued a "buy" rating and issued a $25.00 target price on shares of UroGen Pharma in a research report on Monday, April 28th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, UroGen Pharma presently has an average rating of "Buy" and an average target price of $32.86.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.